These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30603634)

  • 1. VEGF inhibitors in
    Alexander M; Halmos B
    Ann Transl Med; 2018 Dec; 6(23):446. PubMed ID: 30603634
    [No Abstract]   [Full Text] [Related]  

  • 2. Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations.
    Gaughan EM; Cryer SK; Yeap BY; Jackman DM; Costa DB
    Lung Cancer; 2013 Mar; 79(3):193-7. PubMed ID: 23273562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Inhibition of EGFR and VEGF Pathways in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Peravali M; Wang H; Kim C; Veytsman I
    Curr Oncol Rep; 2020 Sep; 22(12):119. PubMed ID: 32945977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with EGFR wild-type non-small-cell lung cancer: the never-ending story.
    Gelsomino F; Agustoni F; Niger M; Valota M; Haspinger ER
    J Clin Oncol; 2013 Sep; 31(26):3291-3. PubMed ID: 23940223
    [No Abstract]   [Full Text] [Related]  

  • 5. EGFR, EGFR TKI, and EMSI: a never-ending story.
    Kim YC
    Transl Lung Cancer Res; 2014 Dec; 3(6):365-7. PubMed ID: 25806321
    [No Abstract]   [Full Text] [Related]  

  • 6. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.
    Yu X; Sheng J; Pan G; Fan Y
    Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibition of EGFR‑VEGF: An effective approach to the treatment of advanced non‑small cell lung cancer with EGFR mutation (Review).
    Wang Q; Zeng A; Zhu M; Song L
    Int J Oncol; 2023 Feb; 62(2):. PubMed ID: 36601768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy.
    Hondelink LM; Ernst SM; Atmodimedjo P; Cohen D; Wolf JL; Dingemans AC; Dubbink HJ; von der Thüsen JH
    Eur J Cancer; 2023 Mar; 181():53-61. PubMed ID: 36638752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Story of Angiogenesis Inhibitors in Non-small-cell Lung Cancer: The Past, Present, and Future.
    Shukla NA; Yan MN; Hanna N
    Clin Lung Cancer; 2020 Jul; 21(4):308-313. PubMed ID: 32291211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in
    Takamochi K; Oh S; Suzuki K
    Oncol Lett; 2013 Nov; 6(5):1207-1212. PubMed ID: 24179496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer.
    Ito T; Nagashima H; Akiyama M; Utsumi Y; Sato H; Chiba S; Sugai M; Ube K; Mori Y; Watanabe K; Fukuhara T; Maemondo M
    Thorac Cancer; 2022 Feb; 13(3):386-393. PubMed ID: 34904383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer.
    Theard PL; Sheffels E; Sealover NE; Linke AJ; Pratico DJ; Kortum RL
    Elife; 2020 Sep; 9():. PubMed ID: 32897190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy in advanced non-small-cell lung cancer.
    Gettinger S
    Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: A cohort study.
    Yu Y; Wang Y; Wu L; Xu X; Zhou H; Wang Q; Zhou J
    Medicine (Baltimore); 2021 Feb; 100(5):e23712. PubMed ID: 33592829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progastrin-Releasing Peptide Precursor and Neuron-Specific Enolase Predict the Efficacy of First-Line Treatment with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Among Non-Small-Cell Lung Cancer Patients Harboring EGFR Mutations.
    Dong J; Tong S; Shi X; Wang C; Xiao X; Ji W; Sun Y
    Cancer Manag Res; 2020; 12():13607-13616. PubMed ID: 33447080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors.
    Chang IS; Jiang SS; Yang JC; Su WC; Chien LH; Hsiao CF; Lee JH; Chen CY; Chen CH; Chang GC; Wang Z; Lo FY; Chen KY; Wang WC; Chen YM; Huang MS; Tsai YH; Su YC; Hsieh WS; Shih WC; Shieh SH; Yang TY; Lan Q; Rothman N; Chen CJ; Chanock SJ; Yang PC; Hsiung CA
    Am J Respir Crit Care Med; 2017 Mar; 195(5):663-673. PubMed ID: 27669169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients.
    Reinmuth N; Jauch A; Xu EC; Muley T; Granzow M; Hoffmann H; Dienemann H; Herpel E; Schnabel PA; Herth FJ; Gottschling S; Lahm H; Steins M; Thomas M; Meister M
    Lung Cancer; 2008 Nov; 62(2):193-201. PubMed ID: 18450321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker testing in patients with advanced non-small cell lung cancer: the never-ending story.
    Malapelle U; Novello S
    Lancet Reg Health Eur; 2024 Mar; 38():100845. PubMed ID: 38476750
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
    Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
    Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired Lung Development and Neonatal Lung Diseases: A Never-Ending (Vascular) Story.
    Thébaud B
    J Pediatr; 2017 Jan; 180():11-13. PubMed ID: 27793337
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.